Genentech to Showcase Ophthalmology Data at ARVO 2026
Genentech is set to present a substantial body of new research highlighting the strength and breadth of its ophthalmology portfolio at the ARVO Annual Meeting 2026, taking place May 3–7 in Denver. As a member of the Roche Group, Genentech continues to emphasize innovation in retinal disease treatment, with a strong focus on preserving vision and improving patient outcomes through advanced therapies and data-driven insights.
Expanding the Frontiers of Ophthalmology Innovation
At this year’s ARVO meeting, Genentech will present more than 45 abstracts, including 20 oral presentations, covering five major retinal conditions: diabetic macular edema (DME), wet age-related macular degeneration (wet AMD), retinal vein occlusion (RVO), geographic atrophy (GA), and uveitic macular edema (UME). These presentations collectively underscore the company’s commitment to addressing a diverse spectrum of retinal diseases that affect millions worldwide.
Central to these discussions will be data on three key therapies: Vabysmo, Susvimo, and the investigational IL-6 inhibitor vamikibart.
Leadership Perspective on Advancing Retinal Care
According to Levi Garraway, the data being presented reflect a broader commitment to advancing ophthalmic science and improving patient care. He emphasized that the findings reinforce Genentech’s dedication not only to innovation but also to delivering meaningful clinical benefits in real-world settings.
A particularly notable highlight is the growing body of real-world evidence supporting Vabysmo’s effectiveness in both treatment-naïve and previously treated patients with wet AMD and DME. These insights are especially valuable because they extend beyond controlled clinical trials into everyday clinical practice, offering a clearer picture of how therapies perform in diverse patient populations.
Real-World Evidence: Vabysmo’s Retinal Drying Impact
One of the most compelling datasets comes from the global VOYAGER study (NCT05476926), which evaluates the real-world performance of Vabysmo. Over a six-month treatment period, the study demonstrated that Vabysmo significantly reduced retinal fluid and improved retinal anatomy. These findings were derived using advanced deep learning algorithms applied to optical coherence tomography (OCT) imaging, allowing for precise and scalable analysis.
The results showed consistent retinal drying across patients, regardless of whether they had previously received anti-VEGF therapies or were new to treatment. This consistency highlights Vabysmo’s potential as a reliable therapeutic option in managing fluid-related retinal diseases, which are a major cause of vision impairment.
In addition to its effectiveness in DME and wet AMD, new data will also explore Vabysmo’s role in treating RVO. Early findings suggest that the drug may offer meaningful benefits in this patient group as well, further expanding its clinical utility.
Susvimo: Sustained Delivery and Reduced Treatment Burden
Another key focus at ARVO 2026 is Susvimo, which utilizes a Port Delivery System (PDS) to provide continuous delivery of medication. Unlike traditional intravitreal injections that require frequent administration, Susvimo offers a long-acting alternative designed to reduce treatment burden while maintaining disease control.
New data from the Phase 3 Pagoda trial in DME patients will highlight patient preferences, showing that many individuals favor the PDS over repeated injections. This preference underscores the importance of not only clinical efficacy but also patient experience in long-term disease management.
Additional analyses will examine retinal fluid, thickness, and leakage in patients treated with the PDS compared to those receiving standard injections. These findings are expected to demonstrate comparable or improved disease control, reinforcing Susvimo’s potential as a transformative option in chronic retinal conditions.
Furthermore, pharmacokinetic simulations will provide insights into how the PDS performs under real-world conditions, offering clinicians valuable guidance on optimizing treatment strategies.
Vamikibart: Targeting Inflammation in Retinal Disease
Genentech will also present early-stage data on vamikibart, an investigational IL-6 inhibitor designed to address underlying inflammation in retinal diseases. Unlike traditional therapies that primarily target vascular factors, vamikibart aims to modulate inflammatory pathways that contribute to disease progression.
Initial results from the Phase 2 ALLUVIUM trial will evaluate the drug’s safety and efficacy in DME patients, while the BARDENAS trial will explore its use in combination with ranibizumab. These studies could pave the way for a new class of treatments that address both vascular and inflammatory components of retinal disease.
Comprehensive Presentation Schedule
Across the conference, Genentech’s presentations will cover a wide range of topics, including:
- Six-month and one-year real-world outcomes from the VOYAGER study
- Long-term safety and effectiveness data from studies such as FARWIDE-nAMD
- Comparative analyses of Vabysmo versus other therapies like aflibercept
- Patient-reported outcomes and preferences in treatment approaches
- Advanced imaging and AI-driven analysis techniques
These sessions will be delivered through a mix of oral presentations and poster sessions, ensuring broad accessibility for attendees.
Commitment to Patient Access and Support
Beyond scientific innovation, Genentech continues to prioritize patient access to its therapies. Through programs like Genentech Access Solutions, the company provides support services designed to help patients navigate insurance coverage, reimbursement, and financial assistance.
Patients prescribed Vabysmo or Susvimo can access dedicated resources, including helplines and personalized support, to minimize barriers to treatment. This holistic approach reflects Genentech’s broader mission to ensure that groundbreaking therapies are not only developed but also made accessible to those who need them.
Driving the Future of Vision Care
The data being presented at ARVO 2026 highlight a critical shift in ophthalmology—from reactive treatment to proactive, personalized care. By leveraging real-world evidence, advanced imaging technologies, and innovative drug delivery systems, Genentech is helping to redefine how retinal diseases are managed.
The company’s expanding portfolio demonstrates a clear focus on improving both clinical outcomes and quality of life for patients. Whether through reducing treatment frequency, enhancing efficacy, or addressing underlying disease mechanisms, these advancements represent meaningful progress in the fight against vision loss.
As research continues to evolve, Genentech’s contributions at ARVO 2026 reinforce its position as a leader in ophthalmology, committed to pushing the boundaries of science and delivering solutions that make a tangible difference in patients’ lives.
About Genentech in Ophthalmology
Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA) and other retinal diseases, including rare and inherited conditions.
Founded 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California
